Table 1.
Oncolytic virus therapy effects in canine cancer cells
| Virus family | Oncolytic virus | Canine cell type | Outcome | Authors, year |
|---|---|---|---|---|
| Adenoviridae | CRAd5 | Osteosarcoma D17, D22, CF11.T, primary cells |
Small amount of virus produced | Ternovoi et al, 200537 |
| CRAd5 + CAV2 knob | Osteosarcoma D17, D22, CF11.T, primary cells |
Large amount of virus produced | Le et al, 200638 | |
| CRAd + p53 | Osteosarcoma CHOS, OOS Mammary adenocarcinoma CHMp, CIPm, CNMm |
Inhibited cell growth | Yazawa et al, 200336 | |
| OC-CAVE1 | Osteosarcoma D17, D22, CF11.T |
Induced cell death | Hemminki et al, 200329 | |
| CAV2 + hyaluronidase | Osteosarcoma Abrams, D17 Melanoma 7CM98, CML1 |
Supported virus growth | Laborda et al, 201439 | |
| Paramyxoviridae | Canine distemper virus | Lymphoma CLL-1390, CLGL-90, 17-71 Lymphocytes and neutrophils from dogs Neoplastic lymphocytes from dogs Osteosarcoma D17 Melanoma DC |
Contain CD150 mRNA Contain CD46 and CD150 mRNA Supported virus infection No detectable CD46 or CD150 mRNA |
Suter et al, 200528 |
| Poxviridae | Vaccinia virus GLV-1h68 |
Mammary tumor ZMTH3, MTH52c |
Increased cell death | Gentschev et al, 200930 Gentschev et al, 201032 |
| Primary soft tissue sarcoma STSA-1 |
Gentschev et al, 201234 Patil 201233 |
|||
| Prostatic carcinoma DT08/40 |
Patil 201233 | |||
| Vaccinia viruses LIVP 1.1.1 and 6.1.1 |
Primary soft tissue sarcoma STSA-1 |
Gentschev et al, 201234 Gentschev et al, 201340 |
||
| Vaccinia virus LIVP 6.1.1 |
Melanoma CHAS Osteosarcoma D17 Prostatic carcinoma DT08/40 |
Gentschev et al, 201340 | ||
| Vaccinia virus GLV-1h109 |
Primary soft tissue sarcoma STSA-1 Prostatic carcinoma DT08/40 |
Increased cell death | Patil 201233 | |
| Vaccina virus GLV-5b451 |
Mammary tumor MTH52c, ZMTH3; Prostatic carcinoma CT1258; Primary soft tissue sarcoma STSA-1 |
Increased cell death | Adelfinger et al, 201568 | |
| Vaccinia virus vvdd + CD40L | Osteosarcoma Abrams Prostatic carcinoma ACE-1 |
Recombinant protein expression | Autio et al, 201441 | |
| Myxoma virus | Hemangiosarcoma | Increased apoptosis of infected cells | Urbasic et al, 201227 | |
| MYXVΔserp2 | Den Transitional cell carcinoma Bliley Primary hemangiosarcoma HSA-1 Primary soft tissue sarcoma STSA-1 |
|||
| Reoviridae | Dearing strain of reovirus serotype 3 | Mast cells Primary cells |
Increased apoptosis | Hwang et al, 201342 |
| Mast cell tumor VIMC, CoMS, CM-MC, HRMC |
Increased apoptosis in some cells | Hwang et al, 201342 | ||
| Lymphoma CL-1, UL-1, CLGL-90, Nody-1, Ema, CLK, GL-1, 17-71, CLBL-1, CLC |
Hwang et al, 201443 | |||
| Melanoma CMeC1, CmeC2, KMeC, LMeC, CMGD2, CMGD5 Mammary carcinoma CIPp, CIPm, CTBp, CTBm, CHMp, CHMm, CNMm Osteosarcoma Abrams, D17, Gracie, MacKinley, Moresco |
Igase et al, 201544 | |||
| Togaviridae | Alphavirus VA7-EGFP |
Osteosarcoma Abrams, D17 |
Induced cell death | Autio et al, 201557 |